KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to 20.83%.

  • West Pharmaceutical Services' EBITDA Margin fell 7700.0% to 20.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.48%, marking a year-over-year decrease of 3800.0%. This contributed to the annual value of 19.7% for FY2024, which is 32200.0% down from last year.
  • As of Q3 2025, West Pharmaceutical Services' EBITDA Margin stood at 20.83%, which was down 7700.0% from 20.05% recorded in Q2 2025.
  • In the past 5 years, West Pharmaceutical Services' EBITDA Margin ranged from a high of 29.61% in Q2 2022 and a low of 15.33% during Q1 2025
  • For the 5-year period, West Pharmaceutical Services' EBITDA Margin averaged around 22.84%, with its median value being 21.98% (2023).
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 95500bps in 2021, then tumbled by -68800bps in 2022.
  • Over the past 5 years, West Pharmaceutical Services' EBITDA Margin (Quarter) stood at 25.18% in 2021, then fell by -27bps to 18.3% in 2022, then grew by 20bps to 21.98% in 2023, then dropped by -3bps to 21.31% in 2024, then decreased by -2bps to 20.83% in 2025.
  • Its EBITDA Margin stands at 20.83% for Q3 2025, versus 20.05% for Q2 2025 and 15.33% for Q1 2025.